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Available online 7 January 2017Nucleic acid-based Toll-like receptor (TLR) ligands are promising adjuvants and immunotherapeutic agents. Combi-
nation of TLR ligands potentiates immune response by providing synergistic immune activity via triggering different
signaling pathways and may impact antigen dependent T-cell immune memory. However, their short circulation
time due to nuclease attack hampers their clinical performance. Liposomes offer inclusion of protein and nucleic
acid-based drugs with high encapsulation efficiency and drug loading. Furthermore, they protect cargo from enzy-
matic cleavagewhile providing stability, and enhancing biological activity. Herein, we aimed to develop a liposomal
carrier system co-encapsulating TLR3 (polyinosinic-polycytidylic acid; poly(I:C)) and TLR9 (oligodeoxynucleotides
(ODN) expressingunmethylatedCpGmotifs; CpGODN) ligands as immunoadjuvants togetherwithprotein antigen.
To demonstrate that this depot systemnot only induce synergistic innate immune activation but also boost antigen-
dependent immune response, we analyzed the potency of dual ligand encapsulated liposomes in long-term cancer
protection assay. Data revealed that CpG ODN and poly(I:C) co-encapsulation significantly enhanced cytokine pro-
duction fromspleen cells. Activation andmaturationof dendritic cells aswell as bactericidal potencyofmacrophages
along with internalization capacity of ligands were elevated upon incubation with liposomes co-encapsulating CpG
ODN and poly(I:C). Immunization with co-encapsulated liposomes induced OVA-specific Th1-biased immunity
which persisted for eight months post-booster injection. Subsequent challenge with OVA-expressing tumor cell
line, E.G7, demonstrated that mice immunized with liposomes co-encapsulating dual ligands had significantly
slower tumor progression. Tumor clearancewas dependent onOVA-specific cytotoxicmemory T-cells. These results
suggest that liposomes co-encapsulating TLR3 and TLR9 ligands and a specific cancer antigen could be developed as
a preventive cancer vaccine.







Preventive cancer vaccine1. Introduction
Innate immune cells recognize microbial (bacterial and viral) com-
ponents via pattern recognition receptors (PRRs) through pathogen-as-
sociated molecular patterns (PAMPs) and differentiate self from non-
self [1,2]. Toll-like receptors (TLRs) are the most extensively studied
PRRs. TLR familymembers are sub-divided to cellmembrane-associated
and endosome-associated receptors. Endosomal TLRs are specialized to
sense nucleic acids. While TLR3 and TLR7/8 recognizes double and sin-
gle-stranded RNA, TLR9 recognizes bacterial DNA or single-stranded
synthetic oligodeoxynucleotides (ODN) expressing unmethylated CpG
motifs (CpGODNs hereafter) [3–6].Multiple TLR triggering could syner-
gistically activate immune response upon multiple agonists engage-
ment [7].tive Diseases (DZNE) Dresden
en, Germany.CpGODNs,which are found frequently in bacterial and viral genome
but rare in mammalian DNA, enhances innate immune response.
Among different ODN classes, D-ODNs (also known as CpG-A type) syn-
thesized as a mixed backbone ODN contain purine/pyrimidine/CpG/pu-
rine/pyrimidine motif and poly G-tail at both ends. This ODN type
induces secretion of type I interferons (IFNs) from plasmacytoid den-
dritic cells (pDCs), and IFN-γ from natural killer (NK) cells [8,9]. It acti-
vates nuclear factor kappa B (NF-κB) and interferon regulatory factor 7
(IRF7) via myeloid differentiation primary response gene 88 (MyD88)
dependent pathway. Polyinosinic-polycytidylic acid (poly(I:C) hereaf-
ter), a synthetic analog of double-stranded RNA initiates signaling cas-
cade through TLR3 and induces type I IFNs along with
proinflammatory cytokines mediated by NF-κB and IRF3 via TRIF-de-
pendent (MyD88-independent) pathway [3,6,10]. Both TLR ligands trig-
ger anti-viral and anti-bacterial immune responses andmimic viral and
bacterial infections. The simultaneous sensing of these two endosomal
TLR ligands by PRRs boosts innate immune response in a synergistic
manner and leads tomore pronounced type I IFNs [11], proinflammato-
ry cytokines, and nitric oxide production [12] with elevated cytotoxic T
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gandsmay help to improve better antigen dependent immunity and an-
titumor activity [15]. Nucleic acid-based TLR ligands are promising
candidates as type 1T helper cell (Th1) specific vaccine adjuvants [8,
16], anti-cancer [17] or anti-allergic therapeutic agents [18], however,
when given in non-encapsulated forms, their clinical performance is
hampered mainly due to in vivo degradation by nucleases or rapid
clearance by serum protein adsorption [19]. To overcome this problem,
several strategies were proposed such as polymer-based nanoparticles
[20,21], polysaccharide complexes [22], liposomes [23–25] aiming to
protect these labilemolecules until they reach their target cells upon ad-
ministration. In our previous studies, we have demonstrated that en-
capsulation of TLR ligands within liposomes not only increases their
stability and protects them from digestion but also enhances their
immunostimulatory and immunotherapeutic breadth [24,26]. The pres-
entwork, aims to extend our previous experience and planned to co-en-
capsulate dual TLR ligands (CpG ODN and poly(I:C)) in liposomes and
test their vaccine potency leading to long-term prevention against can-
cer. We provide evidence that dual ligand encapsulating liposomal vac-
cine improved ligand internalization, enhanced APC function, promoted
a strongTh1-biased antigen-specific immune response and subsequent-
ly prevented animals to develop tumors eight months after immuniza-
tion. We also demonstrated that the dual ligand co-encapsulating
liposomal vaccine induce a long-lasting antigen specific CD8+ memory
T-cell immunity, critically contributing tumor clearance of immunized
mice.
2. Materials and methods
2.1. Reagents
Cholesterol (Chol) and L-α-phosphatidylcholine (PC), lipids that
were used in liposomes preparation was purchased from Sigma Aldrich
(St. Louis, MO, USA) and Avanti Polar Lipids (Alabaster, AL, USA), re-
spectively. TLR9 ligand, CpG ODN D35 5′-GGtgcatcgatgcaggggGG-3′
was kindly provided by Dr. Ken Ishii (IFReC, Japan) [27]. Bases shown
in capital letter have phosphorothioate linkage and those in lower
case have phosphodiester linkages. CpG motif is underlined. Cy5-la-
beled CpGODNwas synthesized in CBER/FDA core Facility and provided
by Dr. Dennis M. Klinman TLR3 ligand poly(I:C) was from Amersham
(Piscataway, NJ, USA) and fluorescein labeled poly(I:C) was from
Invivogen (Toulouse, France).
All cell culture media components were from Gibco (NY, USA) and
Lonza (Lonza, Walkersville, MD, USA). Cytokine ELISA reagents: recom-
binant cytokines, monoclonal unlabeled and biotinylated antibodies
against mIL-6, mIL-12 and mTNF-α were purchased from Biolegend
(San Diego, CA, USA), while streptavidin-alkaline phosphatase, hIFN-α
and mIFN-γ were purchased from Mabtech (Cincinnati, OH, USA) and
hIP10 was from BD (San Jose, CA, USA). P-nitrophenyl phosphate
disodium salt substrate (PNPP) was purchased from Thermo Scientific
(San Jose, CA, USA). Immunoglobulin ELISA reagents; goat anti-mouse
total IgG, IgG1, IgG2c, andmonoclonal antibodies conjugated with alka-
line phosphatase (AP) were from Southern Biotech (Birmingham, AL,
USA). FACS antibodies conjugated to fluorescent chromophores were
obtained from Biolegend. B16-Blue IFN-α/β cells that allow the detec-
tion of bioactive murine type I IFNs were obtained from Invivogen and
used according to the manufacturer's protocol.
2.2. Methods
2.2.1. Preparation of liposomes
Phospholipid stocks were prepared in chloroform and stored at
−20 °C until use. Liposomes were prepared as described earlier [24,
26]. Briefly, lipids (PC:Chol, 1:1 molar ratio, 20 μmol total lipid in 2 ml
chloroform) were mixed and film was formed using rotary evaporator
(ILMVAC, Ilmenau, Germany). Vesicles were generated by hydratingfilm with 1× PBS. These were sonicated five times for 30 s on and 30 s
off at 4 °C using a Vibra Cell Sonicator (Sonics and Materials, Danbury,
CT, USA) to generate smaller unilammellar vesicles (SUV).
Ligand loading within lipid vesicles were performed as described
earlier [24,26]. Briefly, ligands (1 mg of each ligand) and preformed
SUVs (20 μmol) were mixed and snap frozen in liquid nitrogen, and
freeze-dried overnight (VirTis benchtop K, Bieleveld, Germany). Dried
lipid/ODN mixture was rehydrated (1/10 initial volume) using nucle-
ase-free ddH2O and vortexed for 15 s every 5 min for 30 min at room
temperature. Equal volume of PBS was added to the mixture to adjust
the tonicity of the resulting liposomes. Liposomes were washed twice
with 1× PBS (pH: 7.4) to remove the unloaded molecules and centri-
fuged at 16000 g for 1 h. Final concentration of liposomes is 20 μM
lipid/mg ligand. Liposome formulations were stored at 4 °C until use.
2.2.2. In vitro stimulation
Splenocytes isolated from wild type C57BL/6 mice by mashing
spleen with syringe plunger were seeded at 2 × 106 cell/ml (250 μl)
on 96-well cell culture plates and stimulatedwith non- or liposome-en-
capsulated CpG ODN or poly(I:C) or their combinations (2 μg/ml per li-
gand; 20 μmol lipid/1mg ligand) for 36 h at 37 °C in a 5% CO2 incubator.
After stimulation, supernatants were collected. mIL-6 and mIFN-γ se-
cretion was analyzed by ELISA. Additionally, IFN-α/β was assessed
using B16-Blue IFN-α/β reporter cells as described previously [28]. For
uptake and binding experiments, splenocytes were incubated at 37 °C
with labeled non-encapsulated ligands or liposomes encapsulatingfluo-
rescein-labeled poly(I:C) and/or Cy5-labeled CpGODN for 2 h. CpGODN
and/or poly(I:C) positive cells were recorded using BD Accuri C6 flow
cytometer. Cell viability was assessed using cell counting kit-8 (CCK-8,
Dojindo, Kumamoto, Japan) according to the manufacturer's protocol.
All human peripheral bloodmononuclear cell (hPBMC) experiments
were conducted following approval from the Bilkent University Human
Studies Ethical Committee (Approval #: BILHSEC NO:2014-09-02-02)
and with the informed consent of all participants. hPBMCs collected
from healthy donors and purified using Ficoll density centrifugation
were seeded at 1 × 106 cell/ml (200–250 μl) on 96-well cell culture
plates. Cells were stimulated for 24 h. After incubation, supernatants
were collected and used to detect hIP-10 and hIFN-α via ELISA and
cells were stained with fluorescent-labeled anti-CD83 and anti-HLA-
DR, and analyzed by flow cytometry.
RAW 264.7 macrophage cell line (0.5 × 106 cell/ml) was stimulated
with non-encapsulated or liposome-loaded CpG ODN or poly(I:C) or
their combinations (2 μg/ml per ligand; 20 μmol lipid/1 mg ligand)
and TNF-α level was analyzed via ELISA.
Antigen processing was analyzed addition of non-encapsulated or
co-encapsulating ligands (2 μg/ml per ligand; 20 μmol lipid/1 mg li-
gand) together with DQ™-Ovalbumin (2 μg/ml, DQ™-OVA, Molecular
Probes) into APCs (0.5 × 106; BM-DCs, BM-DMs and RAW cells). After
6 h incubation, fluorochrome released upon proteolytic processing
were analyzed by flow cytometry
2.2.3. Generation and stimulation of bone marrow-derived dendritic cells
(BM-DCs) and macrophages (BM-DM)
BM-DCswere generated from bonemarrow isolated from the femur
and tibia of C57BL/6mice incubatingwith GM-CSF and IL-4 as described
previously [29]. The 6–8-day old immature BM-DCs (1 × 106 cell/ml)
were stimulated with non-encapsulated or liposomes (20 μM lipid/mg
ligand) encapsulating CpG ODN (2 μg/ml) or poly(I:C) (2 μg/ml) or
their 1:1 combination at 37 °C in a 5% CO2 incubator. Following 24 h
of incubation, the supernatants were collected and used for measure-
ment of cytokines by ELISA and by B16-Blue IFN-α/β reporter cells.
The expression levels of CD11b, CD11c, MHC-II, CD80 and CD86 in
BM-DCs was analyzed by flow cytometry. Generated BM-DCs were ap-
proximately 80% CD11b+/CD11c+ double positive (Fig. S1A). In addi-
tion, propidium iodide (PI) staining was performed to analyze cell
viability of stimulated BM-DCs.
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femur and tibia of C57BL/6 mice incubated with 30% L929-conditioned
medium (L929-CM) for 6 days. BM-DMs (0.5 × 106 cell/ml) were stim-
ulated with non-encapsulated or liposome-encapsulated CpG ODN or
poly(I:C) or their combinations (0–18 μg/ml from each ligand, 20 μM
lipid/mg ligand) and supernatants were used for nitric oxide (NO) anal-
ysis via Griess reagent (Sigma, St. Louis, MO, USA) and cytokine ELISA.
2.2.4. Immunization study
Animals were kept in the animal holding facility of the Department
ofMolecular Biology andGenetics at BilkentUniversity under controlled
ambient conditions (22 ± 2 °C) regulated with 12 h light and 12 h dark
cycles. They were providedwith unlimited access of food andwater. All
animal studies were conducted with prior approval of the animal ethics
committee of Bilkent University (Approval #: BILAEC NO:2014/32).
Female C57BL/6 mice (6–8 week old) were injected twice intraperi-
toneally (i.p.) two weeks apart with non-encapsulated or encapsulated
CpGODNor poly(I:C) (10 μg each ligand 0.20 μmol liposomes/injection)
or their 1:1 combination plus ovalbumin (OVA, 5 μg/injection). Blood
was collected from tail vein of mice at 1st and 8th month after booster
injection. IgG subtypes were analyzed by end-point ELISA from collect-
ed sera with proper titrations of each samples.
At the end of eight month post-booster injection, animals were sub-
cutaneously inoculatedwith 4 × 106 E.G7-OVA thymoma cells (EL4 cells
stably expressing OVA, ATCC) which were cultured in complete medi-
um containing G418 (1 μg/ml) before injection. Tumor size was mea-
sured daily by digital caliper and recorded for 14 days. Then, animals
were euthanized and spleens were recovered to isolate splenocytes.
IFN-γ-producing CD8+ T-cells against SIINFEKL peptide were deter-
mined by ELISPOT assay.
2.2.5. ELISA and ELISPOT assays
Immulon 2 HB or 1B microtiter plates (Thermo Scientific, San Jose,
CA, USA)were coatedwith anti-cytokine or anti-IgG antibodies (Ab), re-
spectively, and then blocked with PBS-BSA. Serially diluted standards
and culture supernatants or serially diluted mouse sera were added to
plates for overnight at 4 °C. Cytokine was detected using biotinylated
anti-cytokine Ab followed by phosphatase-streptavidin whereas
bound IgG subclasses were detected using alkaline phosphatase
streptavidin-conjugated anti-IgG antibodies and developed by the addi-
tion of PNPP substrate.
Anti-IFN-γ Ab coated Immulon 2 HB plates were blocked with PBS-
BSA in ELISPOT assay. Splenocytes were serially diluted and seeded to
pre-coated plates either with SIINFEKL supplemented (SIINFEKL:OVA
257-264 peptide, Anaspec Inc., San Jose, CA, USA) or justmedia contain-
ing wells. Cells were incubated for further 18 h at 37 °C in a 5% CO2 in-
cubator. IFN-γ+ CD8+ T cell spots were detected using biotinylated
anti-IFN-γ Ab followed by alkaline phosphatase streptavidin and BCIP
dissolved in low melting agarose solutions (Prona, Reducta, Poland; 1/
4, v/v). Spots were counted under binocular stereo microscope.
2.2.6. Statistical analysis
Statistical significant differences between groups were determined
using one-way or two-way ANOVA following Tukey's or Bonferroni
post-hoc comparison and Student's t-test analysis using GraphPad
Prism software (version 5, San Diego, CA, USA). P-values b0.05 were
considered as significant.
3. Results
3.1. IL-6 and interferon type I/II productions were synergistically enhanced
by co-encapsulating poly(I:C) and CpG ODN in neutral liposomes
Our main aim was to combine and enhance the synergistic
immunostimulatory activity of the two nucleic acid-based TLR ligands
known to trigger MyD88 and TRIF dependent signaling cascades byco-encapsulating them in liposomes thereby achieving simultaneous li-
gand delivery to innate immune cells. The prospect of this approachwas
assessed by incubating splenocytes eitherwith non-encapsulated or en-
capsulated poly(I:C) and CpG ODN at 2 μg/ml dose of each ligand. Data
implied that, co-encapsulating poly(I:C) and CpG ODN significantly in-
creased both IL-6 and IFN-γ and IFN-α/β levels over either non-encap-
sulated alone, non-encapsulated dual combined or separately
encapsulated ligands (p b 0.05, one-way ANOVA, Tukey's HSD post
hoc test, Fig. 1A–C). To rule out the toxicity of ligand stimulation on
spleen cells, proliferation assay was conducted using Cell Counting
Kit-8. Results revealed that there was no significant difference between
groups (one-way ANOVA, Tukey's HSD Fig. 1D).
Next, ex vivo immunostimulatory potential of dual TLR ligand co-en-
capsulated liposomes were checked following i.p. injection to C57BL/6
mice (Fig. 1E). Four hours after i.p. treatment, spleen cells were incubat-
ed for further 24 h in cell culture with no additional stimulation and co-
stimulatory (CD86) molecule expressions were analyzed by flow cy-
tometry. Even though the injected initial amounts of non-encapsulated
ligands were 2.5 fold more (25 μg each ligand) than the dual ligand-
loaded liposomal group (10 μg each ligand), cells that received liposo-
mal poly(I:C) plus CpG ODN surpassed non-encapsulated combination
response in terms of CD86 upregulation (Fig. 1E). Of note, 10 μg injec-
tion of each non-encapsulated ligands did not initiate any detectable
CD86 upregulation. These findings revealed that only liposomes co-en-
capsulating both TLR ligands are potent immune inducers than their i)
single or ii) dual non-encapsulated ligand counterparts both in culture
and upon in vivo administration.
3.2. Liposomes co-encapsulating TLR3 and TLR9 ligands enhanced APC
function
Upregulation of MHC class II as well as co-stimulatory molecules
alongwith cytokine production is a direct evidence of improvedAPC ac-
tivity/function. We next assessed the potential of liposomes co-encap-
sulating poly(I:C) and CpG ODN for cellular activation and maturation
of antigen presenting cells (APCs). We found that indeed liposome for-
mulations mediate superior effect than the non-encapsulated ligand
treatments. BM-DCs were generated in the presence of GM-CSF and
IL-4 for six days in culture. Following harvest they were incubated
with non-encapsulated or liposome-loaded TLR ligands. After 24 h
cells were fixed and the number of CD11c+ BM-DCs positive for MHC-
II, CD86 or CD80 was determined by flow cytometry. Our cell gating
strategy throughout these investigations is presented in Fig. S1B.
When the surface marker upregulation levels of non-encapsulated and
liposome-loaded single CpG ODN or poly(I:C) groups were analyzed
there were no significant difference (Fig. S1C). Strikingly, when TLR3
and TLR9 ligands were co-encapsulated within liposomes, it led to sig-
nificantly higher levels of co-stimulatory molecule (CD80 and CD86)
upregulation (Fig. 2A–B and Fig. S1D–E). According to three indepen-
dent experiments, MHC-II+/CD86+ double positive CD11c+ BM-DCs
was higher in co-encapsulated group (74.0 ± 2.0%) than non-encapsu-
lated or liposome-loaded poly(I:C) (57.5 ± 2.6% and 55.0 ± 1.5%, re-
spectively) or non-encapsulated or liposome-encapsulated CpG ODN
(30.5± 2.0% and 35.0±2.0%, respectively) or their separately encapsu-
lated combination (62.5 ± 3.5%) (Fig. 2A). This data suggested that
when dual ligands were encapsulated within liposomes higher MHC-
II+/CD86+ double positive BM-DCs population were obtained com-
pared to non-encapsulated ligand combination treated BM-DCs (Fig.
2B). Of note, in order to rule out that ligand treatments induce non-spe-
cific cell death, at the end of stimulation, cell viability was analyzed
using PI staining and no significant difference between groupswere ob-
served (one-way ANOVA, Tukey's HSD, p b 0.05; Fig. S1F).
When, IL-12 production, a cytokine known to skew immune re-
sponse towards Th1 from BM-DCs in response to ligand treatments
was analyzed from cell supernatants after treatment, we detected that
dual ligand co-encapsulated group generated six fold more IL-12 from
Fig. 1. Liposomes co-encapsulating CpG ODN and poly(I:C) improves in vitro and ex-vivo immunostimulatory effect. Splenocytes were stimulated with non-encapsulated or liposome-
encapsulated (20 μM lipid/mg ligand) CpG ODN and/or poly(I:C) (2 μg/ml from each ligand) for 36 h. Supernatants were collected to detect (A) IL-6 and (B) IFN-γ cytokine levels by
ELISA and (C) IFN-α/β level from reporter cell line (B16-Blue™ IFN-α/β Cells). (D) Cell viability was detected using Cell Counting Kit-8 and absorbance was measured at 450 nm.
Relative cell viability was determined according to naive group. (E) Cells from mice following i.p. injection were harvested and incubated for further 24 h in cell culture. CD86
positivity was assessed by flow cytometry. Results are the average of two independent experiments done in triplicate (mean ± SD). Statistical significance was determined by one-
way ANOVA followed by Tukey's (HSD) test. ns: non-significant; *p b 0.05; **p b 0.01; ***p b 0.001.
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~4 fold more IL-12 over non-encapsulated ligand combination treated
groups (Fig. 2C). Furthermore, type I IFN secretion from BM-DCs treated
with co-encapsulated CpG ODNplus poly(I:C) was found to be ~2.0 fold
and ~1.7 foldmore compared to non-encapsulated combination treated
group and separately encapsulated CpG ODN and poly(I:C) group, re-
spectively (Fig. 2D).
In a separate experiment, bone marrow derived macrophages (BM-
DM) were generated and incubated with non-encapsulated or lipo-
somes co-encapsulating ligands for 24 h. Nitric oxide (NO), and IL-12
levels were determined by Griess reagent, ELISA, respectively. WhileIL-12 production in co-encapsulating group, (CpG ODN + poly(I:C))L,
was consistently higher than non-encapsulated combination at all
doses except at 18 μg/ml dose, NO production was elevated only in co-
encapsulated group at 18 and 6 μg/ml doses (Two-way ANOVA,
Bonferroni; Fig. 3A and B). Moreover, 2 fold more TNF-α production
was detected from (CpG ODN + poly(I:C))L treated cells (Fig. 3C).
Effective antigen presentation could only be achievedwhen both an-
tigen and adjuvant simultaneously internalized by APCs. Liposomes are
excellent candidates for simultaneous delivery of their cargo. To address
this, DQ™-OVA, was used either with non-encapsulated or with dual li-
gand co-encapsulated liposomes. DQ™-OVA is an ovalbumin protein
Fig. 2. Liposomes co-encapsulating CpGODN andpoly(I:C) promoted BM-DCmaturation. Immature BM-DCswere incubated at 37 °Cwith non-encapsulated or liposomal CpGODN and/or
poly(I:C) (2 μg/ml from each ligand) for 24 h. Expression levels of CD86 andMHC-II were analyzed by flow cytometry: (A) representative dot plots. (B) Fold induction profiles of double
positive cells. Average of three independent experiment are presented (Student's t-test, p = 0.02). Following stimulation, supernatants were collected to determine (C) IL-12 levels by
ELISA and (D) IFN-α/β levels by reporter cell line. Results are average of two independent experiments done in triplicate (mean ± SD). Statistical significance was determined by
ANOVA followed by Tukey's (HSD) test. ns: non-significant; *p b 0.05; **p b 0.01; ***p b 0.001.
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fluorescence could be detected when ovalbumin is hydrolyzed. We
assessed antigen delivery and processing ability of liposomal constructs
following incubation with BM-DC, BM-DM and RAW 264.7 cells (Fig.
3D). All data was normalized to degradation level of each treatment
group incubated at 4 °C. We found that 6 h after incubation, fluores-
cence signal was significantly high for liposome treated cells compared
to non-encapsulated ligand treated cells (t-test, p b 0.001).
When thefindings fromFigs. 2 and 3were taken together, liposomes
co-encapsulating CpG ODN and poly(I:C) i) induced robust cytokine
production, ii) magnified bactericidal activity, iii) upregulated costimu-
latory molecules, and iv) improved APC function.
3.3. Co-encapsulation of poly(I:C) and CpG ODN within liposomes aug-
mented ligand binding by immune cells
The mechanism of the enhanced synergistic innate immune activa-
tion could be due to effective internalization of liposomal ligands by
the target cells.
To verify whether augmented immune activity correlated with the
improved cellular uptake, non-encapsulated and liposomal forms of
Cy5-labeled CpG ODN and fluorescein-labeled poly(I:C) ligands were
used to stimulate mouse immune cells and ligand specific flurochrome
positivity was analyzed by flow cytometry (Fig. 4). After 2 h incubation,
non-encapsulated dual ligand treated cells had 5.2% and 1.3% (for CpG
ODN and poly(I:C) signal, respectively) positivity, whereas dual ligand
co-encapsulated treatment gave 12.5% and 6.5% CpG ODN and poly(I:C)
positivity, respectively (Fig. 4A). Consequently, co-encapsulation byliposomes provided ~2.5 foldmore CpGODNand ~5 foldmore poly(I:C)
binding.When relativeMFI values of the treatmentswere analyzed, this
improvement in ligand binding was more pronounced (Fig. 4B). Thus,
the improved uptake ability of both ligands via liposome encapsulation
led to a robust synergistic immuneactivity. Furthermore, thisfinding re-
vealed that rather than encapsulating TLR3 and TLR9 ligands in different
liposomes, co-encapsulating themwithin a single carrier ismore prefer-
able (Fig. 4C).
3.4. Antigen loading together with dual TLR ligands within liposomes pro-
vides magnified and sustained antigen specific IgG response
After observing that poly(I:C) and CpG ODN co-encapsulated within
liposomes boosted Th1-biased immune activation and improved APC
function, we next investigated the potential of this system as a preven-
tive vaccine (Fig. 5A). After injecting C57BL/6mice twice (primary@ d:0
and booster @ d:14) with indicated formulations (Fig. 5B), sera were
collected from animals following tail bleedings and anti-OVA IgG levels
were detected by end-point ELISA. Serum titrations for total IgG, IgG1
and IgG2c subtypes were analyzed following 1st and the 8th month
post-booster injections (Fig. 5B–D). The rationale of the immunization
study was to identify anti-OVA antibody persistence among groups. As
seen in Fig. 5B, (CpG ODN + OVA)L+(poly(I:C) + OVA)L and (CpG
ODN + poly(I:C) + OVA)L groups gave the highest total IgG titers at
the end of eight months post-booster injection. If one expects to raise
a Th-1 biased anti-OVA immunity upon immunization, the vaccine can-
didate should reduce IgG1 and promote IgG2c (or IgG2a in Balb/cmice).
When our results by the end of eight months of antibody titer is
Fig. 3. Liposomes co-encapsulating CpG ODN and poly(I:C) induce pronounced macrophage activation. BM-DM were generated with 30% L929 supplemented medium and stimulated
with non-encapsulated or liposome co-encapsulating CpG ODN and poly(I:C) (0–18 μg/ml per each ligand). (A) IL-12 and (B) NO levels were determined by ELISA and Griess reagent,
respectively. Statistical significance was determined by two-way ANOVA followed by Bonferroni test (non-encapsulated vs. co-encapsulated liposome). ns: non-significant; **p b 0.01;
***p b 0.001. (C) RAW 264.7 cells were stimulated with non-encapsulated ligands or co-encapsulated CpG ODN and poly(I:C) liposomes for 24 h and TNF-α secretion was determined
by ELISA (one-way ANOVA, Tukey's HSD test). (D) Antigen processing was analyzed after the addition of non-encapsulated ligands or co-encapsulated ligands (2 μg/ml from each
ligand) together with DQ™-OVA (2 μg/ml) onto BM-DCs, BM-DMs or RAW 264.7 cells by flow cytometry (non-encapsulated ligands vs co-encapsulated ligands; Students t-test,
*p b 0.05, **p b 0.01, ***p b 0.001). Results are represented as average of two independent experiments done in triplicate (mean ± SD).
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highest IgG2c titers and lower IgG1 titer (compare Fig. 5C and D last
three bars).
Collectively this data pointed out that antigen and dual adjuvants co-
encapsulated within liposomes achieved simultaneous
antigen + adjuvant delivery to APC and triggered long-lasting,
sustained anti-OVA specific Th1-biased immunity.
3.5. Vaccine formulations containing both CpG ODN and poly(I:C) generat-
ed persisting memory CD8+ T cells and prevented tumor formation
We then sought whether OVA immune animals could effectively
control or eradicate tumor inoculation. At the end of eight month
post-booster injection, mice were subcutaneously (s.c.) inoculated
with 4 × 106 E.G7 cells (EL4 cells transduced to express OVA) and
were followed for 14 days. The individual tumor development was
followed daily with electronic caliper. In all animals that were immu-
nizedwith saline, tumor formationwas observed 4 days post-E.G7 inoc-
ulation. The median of tumors in naive group reached 402.5 mm3. The
tumor sizes at day 14 post-inoculation are presented in Fig. 6A. Animals
immunized with liposomal formulations showed reduced tumor sizes.
Mice that received (CpG ODN + poly(I:C) + OVA)L vaccine and chal-
lenged 8 months later gave 75% (n = 6/8) tumor free animals at the
end of d = 14. All groups were significantly different than naive group(one-way ANOVA, p b 0.01) and the variance between co-encapsulated
group and independent ligands encapsulated liposome group were sig-
nificantly different (F test, p = 0.0019).
OVA specific memory T-cells is one of themajor contributing cells to
eliminate OVA-expressing tumor cells. The tumor specific CD8+ T-cell
numbers were analyzed by IFN-γ ELISPOT assay. The splenocytes from
immunized animals were treatedwith CD8+ T cell specific OVA peptide
(SIINFEKL) for 18 h. The data revealed that co-administration of
ligands+OVA tomice eitherwith separately encapsulated or co-encap-
sulated liposomes significantly increased IFN-γ+ CD8+ T cell numbers
(Fig. 6B). Surprisingly, (CpG ODN+ poly(I:C) + OVA)L vaccine treated
animals did not generate significantly higher CC8+ memory T-cell
number compared to (CpGODN+OVA)L+(poly(I:C)+OVA)L vaccine
treated group.
Collectively, our findings implied that a combination of poly(I:C) and
CpG ODN adjuvants in liposomal formulations induced stronger and
persistent humoral and cellular anti-OVA specific immune response suf-
ficient to eradicate tumors.
3.6. Synergistic immune activation elucidated in hPBMCs with liposomes
co-encapsulating poly(I:C) and CpG ODN
In mice, due to strong in vivo anti-tumoral immune response gener-
ated upon co-encapsulated (CpG ODN + poly(I:C) + OVA)
Fig. 4. Liposomes co-encapsulating CpG ODN plus poly(I:C) improves cellular uptake. Splenocytes were incubated at 37 °C with non-encapsulated ligands or liposomes encapsulating
fluorescein-labeled poly(I:C) and/or Cy5-labeled CpG ODN (2 μg/ml each) for 2 h. (A) Representative dot-plots and (B) relative MFI values of uptake & binding of CpG ODN or
poly(I:C). (C) Cy5-CpG ODN and fluorescein-poly(I:C) double positive cell percent after non-encapsulated ligand or liposomal ligand treated cells for 2 h (Student's t-test; *p b 0.05;
**p b 0.01; ***p b 0.001 between groups). Data represents average of two independent experiments done in triplicate (mean ± SD).
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challenge. We next sought to establish whether this formulation trig-
gers hPBMCs to the same extent that we observed in mice. Therefore,
hPBMCs were collected from healthy donors and stimulated with i)
non-encapsulated, ii) encapsulated and iii) co-encapsulated CpG ODN
and/or poly(I:C) for 24 h. All hPBMCs produced significantly higher
levels of IFN-α (A, left panels) when treated with (CpG ODN +
poly(I:C))L group. Similarly, the IP10 production was more with co-en-
capsulated liposomal group compared to non-encapsulated or separate-
ly encapsulated ligand combinations (Fig. 7A, right panels). In addition,
percentages of HLA-DR+/CD83+ hPBMCs were significantly higher
in cells treated with dual ligands co-encapsulated into liposomes
(one-way ANOVA, Tukey's HSD, p b 0.05 between non-encapsulated
vs co-encapsulation, and between separately vs co-encapsulation
groups; Fig. 7B).Fig. 5. Immunization with liposomes co-encapsulating CpG ODN, poly(I:C), and/or ovalbumin
group) were immunized twice with 14 day intervals with liposome encapsulated CpG ODN
(OVA, 5 μg/animal) and sera was collected from tail vein 1st and 8th month post-booster injec
end-point ELISA (mean ± SD). Statistical significance was determined by one-way ANOVA follIn conclusion, co-encapsulation of poly(I:C) and CpG ODNwithin li-
posomes enhanced secretion of interferon alpha andmaturation of APCs
in human immune cells. A promising finding implicating that these
combinations could be translated to clinical applications.
4. Discussion
There is no doubt that TLR therapeutics soon will be in the clinics.
The endosomal-associated TLR ligands senses nucleic acid ligands and
are one of the most promising candidate bio-drugs as immunothera-
peutic agents. Clinical trials harnessing various nucleic acid TLR ligands
are underway aiming to cure diseases like cancer, allergy, autoimmune
or autoinflammatory and infectious diseases. One of the promising area
for TLR mediated therapeutics is to utilize them as vaccine adjuvants or
immunoprotective agents where there is no available vaccinespromotes Th-1 biased immunity. (A) Immunization schedule. C57BL/6 female mice (8/
(10 μg/animal) and/or poly(I:C) (10 μg/animal) or their combinations with ovalbumin
tion. (B) Diluted sera were used for OVA specific (B) total IgG, (C) IgG1 and (D) IgG2c by
owed by Tukey's (HSD) test. ns: non-significant; *p b 0.05; **p b 0.01; ***p b 0.001.
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lating these labile nucleic acid-based agents (i.e. ds RNA or CpG DNA)
in stable formwithin proper depot systems improve their bioavailability
and bioactivity at the of the target cell sites. We previously demonstrat-
ed that liposomes enhance in vivo immunostimulatory activity of TLR li-
gands along with ligand sparing effect and improved shelf-life [17,24,
26]. In this study, liposomes are used to co-encapsulate two important
TLR ligands, expanding their breadth of synergistic immune activity,
therefore, improving their immunoadjuvant effect upon co-encapsulat-
ing antigen of interest. Here, we provide evidence that these liposomes
encapsulating dual TLR ligands i) upregulates costimulatory molecules,
ii) magnifies proinflammatory and inflammatory cytokine secretion, iii)
providesmore efficient ligand internalization, iv) improvesmacrophage
bactericidal activity v) boosts APC function of DCs and vi) promotes de-
velopment of Th1 type immunity and vii) in mice provides long lasting
antigen specific humoral and cell-mediated immunity capable of
preventing E.G7 tumor development even after eight months post-
booster injection.
Low doses of non-encapsulated single TLR ligand could be insuffi-
cient to mount an appreciable degree of immune activation however;
combination of ligands even at low doses (here, 2 μg/ml of each ligand
within liposomes) could trigger synergistic immune response when
given within liposomes. Using MyD88 independent and dependent li-
gands trigger multiple signaling pathways improves the breadth of im-
mune activation [30]. Krummen et al. demonstrated that the synergistic
immunostimulatory action between TLR ligands was more pronounced
than their standalone counterparts when MyD88 and TRIF-dependent
signaling, like CpG ODN and poly(I:C), respectively, was combined
[31]. In addition, studies showed the elevated immune response when
CpGODN is administered togetherwith poly(I:C) [11–14,29,32].We en-
capsulated these two ligands to enhance their synergistic activation and
utilized them as novel form of long term effective anti-cancer vaccine.
The demonstration of synergy between CpG ODN and poly(I:C) follow-
ing co-encapsulation within liposomes were tested on murine
splenocytes. Co-encapsulating CpG ODN plus poly(I:C) led to higher
levels of secretion of type I and II IFNs, and IL-6 than non-encapsulated
or loaded single or combinational ligands by splenocytes (Fig. 1). Co-en-
capsulationwas stronger than separately encapsulated ligands. This im-
proved activity suggested that co-encapsulating TLR3 and TLR9 ligands
can activate immune response even better than their non-encapsulated
combinations.
Additionally, type I IFN and IL-12 secretion was significantly elevat-
ed by co-encapsulation when compared with non-encapsulated or sep-
arately encapsulated dual ligands. Supporting our findings, it was
shown that, IL-12 production from BM-DCs was synergistically in-
creased with non-encapsulated combination [31,32]. However, in
those studies, non-encapsulated poly(I:C) plus CpG ODN could not
achieve to synergistically increase neither CD86 surface marker nor
type I IFN secretion.
Liposomes act as a depot delivery system and improve cellular up-
take of the ligands. Previously, we reported that uptake of CpG ODN is
higher by immune cells when it is encapsulated within sterically stabi-
lized cationic liposomes (SSCL) [26]. In this study, we showed that CpG
ODN uptake was even higher when administered together with
poly(I:C) into liposomes. More importantly, we provide evidence that
dual uptake of ligands amplified sixfold more than non-encapsulated
or separately encapsulated dual ligands (Fig. 4). In a study, lipofecta-
mine mixed phosphorothioate-modified CpG ODN plus poly(I:C) was
demonstrated to block uptake of poly(I:C) by tumor cells [34]. Here,
since our ligands are encapsulated rather than complexed with the
nanocarrier, we did not observe any blockage ofwither of the ligand up-
take. Besides, the uptake increase would be explained by the decreased
size of liposomes co-encapsulating dual ligands compared to unloaded
liposomes (Fig. S2).
Simultaneous presentation of adjuvants and antigen plays an impor-
tant role in the quality and quantity of immune response against proteinantigen [35,36]. Encapsulation of antigen with adjuvant within delivery
vehicle overcomes random antigen and adjuvant uptake by APCs, fur-
thermore it increases the internalization of exogenous antigen [20,26,
35–37]. We show that, higher IgG2c production was maintained over
the course of 8 months only when mice were immunized with lipo-
somes co-encapsulating antigen and adjuvants rather than standalone
counterparts (Fig. 5).
In the present work, both co- and separately encapsulated groups
protected immunized mice against tumor formation. However, when
the content of the separately encapsulated liposome formulation, it
contained two fold more antigen than co-encapsulated formulation
(i.e. (CpG ODN + OVA)L+(poly(I:C) + OVA)L vs CpG ODN +
poly(I:C) + OVA)L). Therefore, it is important to note that co-encapsu-
lated group yielded more pronounced Th1-biased anti-OVA immunity
with 2-fold less antigen.
In a study, effect of lipid structure and size of DDA:TDB liposomes
were investigated on cellular and humoral responses and CpG ODN
and/or poly(I:C)were co-encapsulated or complexed to enhance immu-
nogenicity of liposomes. Results revealed that co-encapsulating dual li-
gands into DDA:TDB liposomes boosted total IgG and induced Ag-
specific T cell activation in multilamellar vesicles (MLV) not in SUV
[37]. In that study, three immunizations with 250 μg DDA:DSPC, 50 μg
TDB, 20 μg CpG, 50 μg poly(I:C) and 20 μg OVA were employed for
every injection. As DDA:TDB liposomes have immunogenic effect by
its own [38], Our vaccine candidate composed of 10 μg CpG, 10 μg
poly(I:C), and 5 μg OVA, in neutral liposomes is the first study demon-
strating enhanced synergy of CpGODN and poly(I:C)when co-encapsu-
lated into non-immunogenic liposomes (Fig. S3) together with antigen
that with immunization, both Th1 and CTL responses were sustained
over the course of 8 months, and successfully protects immunized
mice to develop tumors. The aim of the present study is to develop a
cancer vaccine that can protect individuals long after they are vaccinat-
ed against a specific cancer antigen. It is true that much shorter tumor
challenge intervals are used for therapeutic vaccinations. However,
CpGODNand poly(I:C) is known tomediate antigen independent clear-
ance of tumor cells. In this study, since we aimed to address the contri-
bution of memory CD8+ T-cells, we chose to challenge our animals
eight month after booster injection, therefore, TLR ligands mediated
non-specific innate immune activation could not be responsible from
tumor elimination.5. Conclusion
Liposomes co-encapsulating CpGODNand poly(I:C) boosted cellular
uptake of the cargo, improved proinflammatory cytokine production
alongwith type I/II IFN secretion, aswell as co-stimulatorymolecule up-
regulation leading to a pronounced APC function and antigen process-
ing. The co-encapsulation of OVA antigen into liposome vesicles
created a long-lasting anti-cancer immune response. The heightened
Th1 immunity in addition to enhanced OVA-specific memory CD8+ T
cell response helped to control tumor development. Similar immune
stimulatory activity was reproduced with human peripheral mononu-
clear cells, supporting the applicability for human use. In conclusion,
the present liposomal vaccine candidate offers an effective antigen
and adjuvants co-encapsulation approach and could be developed as
preventive vaccine for human use against cancer or viral diseases.Conflict of interest
The authors confirm that there are no known conflicts of interest
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Fig. 6.Mice immunized with liposomes co-encapsulating CpG ODN+ poly(I:C) + OVA resist tumor development long after booster injection. Following 8th month of booster injection,
immunized animals were inoculated with OVA expressing E.G7 thymoma cells (4 × 106 cells/animal). (A) Tumor volume was measured daily for a duration of 14 days following the
appearance of palpable tumor. (B) At the end of tumor follow-up mice were sacrificed and splenocytes were isolated and IFN-γ+ CD8+ T-cells were detected stimulating serially
diluted splenocytes with OVA 257–264 peptide (SIINFEKL) for 18 h by ELISPOT method. Data were presented as mean ± SD. Statistical significance was determined by one-way
ANOVA followed by Tukey's (HSD) test. ns: non-significant; *p b 0.05; **p b 0.01, ***p b 0.001.
Fig. 7. Immune response of human PBMCs following treatment with liposome co-encapsulating CpG ODN plus poly(I:C). PBMCswere isolated from healthy donors' blood and stimulated
with non-encapsulated or liposome encapsulating CpGODN and/or poly(I:C) for 24 h. Supernatantswere used for (A) IFN-α and IP-10 cytokine ELISA. Triplicatewells (mean±SD) of four
healthy donors are presented. (B) CD83 andHLA-DRpositive PBMCs (three healthy donors)were analyzed viaflow cytometry. Statistical significancewas determined by one-way ANOVA
followed by Tukey's (HSD) test. ns: non-significant; *p b 0.05; **p b 0.01; ***p b 0.001.
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